Class summary at a glance.

Every drug in the Tetracycline-class Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $185.4Mcombined across class
Total Rx claims: 22K9K unique beneficiaries
Generic mfrs (active): 4across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Omadacycline

Brand: NUZYRA · 17K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2019-02-01

Brand-only (no generics) 19 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $181.7M

Class share

98%

of class CY24 spend

View profile →

Tigecycline

Brand: Tygacil · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2008-06-15

4 generic mfrs 46 plans require PA